Literature DB >> 6334655

The inhibition of lymphocyte stimulation by autologous human metastatic melanoma cells correlates with the expression of HLA-DR antigens on the tumor cells.

D Taramelli, G Fossati, A Balsari, R Marolda, G Parmiani.   

Abstract

Previous studies indicated that peripheral blood lymphocytes from patients (Pt-PBL) with lymph node metastatic melanomas proliferated in vitro and developed into tumor-restricted cytotoxic lymphocytes in response to alloantigens or interleukin 2 (IL-2). However, Pt-PBL were not stimulated by irradiated autologous metastatic melanoma (Auto-Me) cells. In the present study we report that the lack of stimulatory activity of Auto-Me cells may be due to a suppressive effect exerted by Auto-Me cells on the responder lymphocytes. In fact, we found that in 62% of cases examined, the addition of 5-10% Auto-Me cells to Pt-PBL cultures strongly inhibited both proliferation and the generation of tumor cytotoxic lymphocytes induced by alloantigens or IL-2. The inhibition was dose-dependent and tumor-restricted, and was not due either to toxicity, medium depletion or IL-2 absorption by Auto-Me cells. Normal fibroblasts, K562 cells and autologous E-lymphocytes were not suppressive. Auto-Me cells were able to inhibit Pt-PBL responses only when added during the first 24 h of culture and not later. Phenotypic analysis of Auto-Me cells using monoclonal antibodies directed against HLA-A,B,C, HLA-DR and melanoma-associated antigens revealed that the expression of high levels of DR antigens on Auto-Me cells was associated with an elevated suppressive activity. Conversely, Auto-Me cells with low or undetectable levels of DR antigens were not inhibitory. Furthermore, the increased expression of DR antigens on Auto-Me cells obtained by in vitro treatment with human interferon gamma (IFN-gamma) also resulted in an increased suppressive activity. We conclude that HLA-DR+ metastatic melanoma cells can interfere with the generation of an anti-tumor immune response, thus potentially favoring the escape of the tumor from the host's control mechanism.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6334655     DOI: 10.1002/ijc.2910340610

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  23 in total

1.  MHC class II antigen expression in normal human epidermis.

Authors:  M M Carr; E McVittie; K Guy; D J Gawkrodger; J A Hunter
Journal:  Immunology       Date:  1986-10       Impact factor: 7.397

2.  Cancer patients' lymphocytes contain CD3+ CD4+ cells that proliferate in response to autologous tumor cells in the presence of exogenous low-dose interleukin-2 and autologous accessory cells.

Authors:  M Radrizzani; M Quaia; B Benedetti; S Andreola; M Vaglini; E Galligioni; G Fossati; G Parmiani
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

3.  B cells from chronic lymphocytic leukemia (CLL) patients are strong inducers of proliferation and major histocompatibility complex (MHC)-unrestricted [natural killer (NK)-like] cytotoxicity in normal T-lymphocytes.

Authors:  L Matera; R Foa; M Massaia; M Giovarelli; F Veglia; A Cesano; P Lusso; A Piazza; D Santoli
Journal:  J Clin Immunol       Date:  1989-07       Impact factor: 8.317

4.  Proliferative response of lymphocytes from ovarian cancer patients to autologous tumor cells.

Authors:  P Allavena; P Lo Presti; M Di Bello; V Lucchini; A Lissoni; G Zanetta; C Mangioni; A Mantovani
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

5.  Inhibition of lymphokine-activated killer cell generation by cultured tumor cell lines in vitro.

Authors:  P J Guillou; P C Sedman; C W Ramsden
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

6.  Lysis by interleukin 2-stimulated tumor-infiltrating lymphocytes of autologous and allogeneic tumor target cells.

Authors:  M Radrizzani; C Gambacorti-Passerini; G Parmiani; G Fossati
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

7.  Expression of HLA-DR antigens on tumour cells does not contribute to skin reactivity to autologous cholesteryl hemisuccinate (CHS)-treated tumour cells in patients with metastatic melanoma.

Authors:  M Munzarová; D Zemanová; J Kovarík; Z Pacovský; A Rejthar; J Bártek
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

8.  In vivo delayed rejection of tumors and inhibition of delayed-type hypersensitivity by HT-29 human colonic adenocarcinoma cell line.

Authors:  G J Pommier; F L Garrouste; D Bettetini; J M Culouscou; M M Remacle-Bonnet
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

9.  Depression of cell-mediated immunity by tumour cell products: induction of resistance by immunotherapeutically active extracts of bovine ocular squamous cell carcinoma.

Authors:  M Nelson; D S Nelson; V K Kuchroo; P B Spradbrow; P A Jennings
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

10.  Influence of LAK cells on expression of HLA-DR antigen on laryngeal carcinoma cell line in new culture systems.

Authors:  H Kumazawa; T Kumazawa; T Tachikawa; S Sai; T Yamashita; K Kawamoto
Journal:  Eur Arch Otorhinolaryngol       Date:  1993       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.